Home » Newsletters » BioWorld Science

BioWorld Science

April 19, 2017

View Archived Issues

Novartis and Allergan collaborate on phase IIb study in NASH

OncoMed reports endpoint not met in tarextumab study, discontinuation of brontictuzumab trial

ADDF investment supports progression of NDX-1017 towards phase I trials for Alzheimer's disease

argenx achieves preclinical milestone with ARGX-115 under AbbVie collaboration

BioSpecifics opens phase I study of Xiaflex for uterine fibroids

AAV8-whirlin restores balance and auditory function in preclinical model of Usher syndrome

Ionis and Ribo collaborate on RNA-targeted therapeutics in China

Interim results from a phase II trial of tetravalent dengue vaccine candidate

Regen identifies new series of compounds that activate NR2F6 nuclear receptor

Encouraging 24-week data reported from phase III study of burosumab in X-linked hypophosphatemia

Cardinal Health to acquire select businesses from Medtronic's PMR division

First report of a novel somatic mutation in PRKAR1A gene in Sertolli cell tumor

Nivalis Therapeutics and Alpine Immune Sciences to merge

Temple University, Cognition Therapeutics discover sigma-2 receptor ligands for Alzheimer's disease

Mateon reports interim data from FOCUS study of CA4P in platinum-resistant ovarian cancer

Cinclus Pharma enrolling participants in first-in-human trial of X-842

AstraZeneca targets Mcl-1 with AZD-5991 for hematological cancers

Argos updates status of ADAPT phase III trial of rocapuldencel-T in metastatic renal cell carcinoma

Ludwig Institute for Cancer Research identifies FEN1, ERCC5 and EXO1 nucleases inhibitors

Pfizer presents beta-secretase 1 inhibitors

The University of Florida discovers antimicrobial agents

ADX-102 granted U.S. orphan status for congenital ichthyosis

INCB-039110 receives FDA orphan designation for graft-versus-host disease

Vivace Therapeutics patents YAP1/TEAD interaction inhibitors

ADAMTSL3 found as a candidate biomarker in ischemic stroke

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...